Amylyx Pharmaceuticals, Inc. develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid.
Market Cap | 2.368 Billion | Shares Outstanding | 57.86 Million | Avg 30-day Volume | 843.528 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | 0 |
Price to Book Value | 11.4402 | Operating Margin | 0.0 | Enterprise Value | 1.485 Billion |
Current Ratio | 5.275 | EPS Growth | 0 | Quick Ratio | 4.985 |
1 Yr BETA | 1.0456 | 52-week High/Low | 41.25 / 6.51 | Profit Margin | 0.0 |
Operating Cash Flow Growth | 0.0 | Altman Z-Score | 24.9426 | Free Cash Flow to Firm | 0 |
Earnings Report | 2023-03-29 |
Please sign in first
none
19 Thousand total shares from 10 transactions
5 Thousand total shares from 1 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
FRATES JAMES M CHIEF FINANCIAL OFFICER |
|
68,840 | 2023-01-06 | 3 |
YERAMIAN PATRICK D CHIEF MEDICAL OFFICER |
|
409,227 | 2023-01-06 | 1 |
KLEE JUSTIN B. CO-CHIEF EXECUTIVE OFFICER |
|
5,787,080 | 2023-01-06 | 2 |
COHEN JOSHUA B CO-CHIEF EXECUTIVE OFFICER |
|
5,787,080 | 2023-01-06 | 2 |
OLINGER MARGARET CHIEF COMMERCIAL OFFICER |
|
429,453 | 2023-01-06 | 1 |
|
7,680,598 | 2022-12-31 | 1 | |
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC VIKING GLOBAL OPPORTUNITIES GP LLC |
|
5,770,536 | 2022-09-08 | 1 |
|
5,895,280 | 2022-07-06 | 1 | |
|
19,000 | 2022-06-09 | 1 | |
|
19,000 | 2022-06-09 | 1 | |
|
19,000 | 2022-06-09 | 1 | |
|
19,000 | 2022-06-09 | 1 | |
MAZZARIELLO GINA CHIEF LEGAL OFFICER |
|
223,000 | 2022-02-22 | 2 |
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC VIKING GLOBAL OPPORTUNITIES GP LLC |
|
0 | 2022-01-11 | 1 |
|
2,300,000 | 2022-01-11 | 0 | |
|
21,094,458 | 2022-01-06 | 1 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
KLEE JUSTIN B. - Director - Officer CO-CHIEF EXECUTIVE OFFICER |
2023-01-10 19:12:48 -0500 | 2023-01-06 | S | 4,122 | $36.08 | a | 2,894,463 | direct | yes | 1.6204 | -5.1634 | 2.9662 | 3 | -5.1634 | 6 | |
KLEE JUSTIN B. - Director - Officer CO-CHIEF EXECUTIVE OFFICER |
2023-01-10 19:12:48 -0500 | 2023-01-06 | S | 1,846 | $36.79 | a | 2,892,617 | direct | yes | 1.6204 | -5.1634 | 2.9662 | 3 | -5.1634 | 6 | |
2023-01-10 19:19:15 -0500 | 2023-01-06 | S | 1,660 | $36.08 | a | 215,098 | direct | yes | 1.6204 | -5.1634 | 2.9662 | 3 | -5.1634 | 6 | ||
2023-01-10 19:19:15 -0500 | 2023-01-06 | S | 743 | $36.79 | a | 214,355 | direct | yes | 1.6204 | -5.1634 | 2.9662 | 3 | -5.1634 | 6 | ||
2023-01-10 19:20:38 -0500 | 2023-01-06 | S | 1,836 | $36.08 | a | 34,831 | direct | yes | 1.6204 | -5.1634 | 2.9662 | 3 | -5.1634 | 6 | ||
2023-01-10 19:20:38 -0500 | 2023-01-06 | S | 822 | $36.79 | a | 34,009 | direct | yes | 1.6204 | -5.1634 | 2.9662 | 3 | -5.1634 | 6 | ||
COHEN JOSHUA B - Director - Officer CO-CHIEF EXECUTIVE OFFICER |
2023-01-10 19:20:58 -0500 | 2023-01-06 | S | 4,122 | $36.08 | a | 2,894,463 | direct | yes | 1.6204 | -5.1634 | 2.9662 | 3 | -5.1634 | 6 | |
COHEN JOSHUA B - Director - Officer CO-CHIEF EXECUTIVE OFFICER |
2023-01-10 19:20:58 -0500 | 2023-01-06 | S | 1,846 | $36.79 | a | 2,892,617 | direct | yes | 1.6204 | -5.1634 | 2.9662 | 3 | -5.1634 | 6 | |
2023-01-10 19:22:45 -0500 | 2023-01-06 | S | 1,405 | $36.08 | a | 204,928 | direct | yes | 1.6204 | -5.1634 | 2.9662 | 3 | -5.1634 | 6 | ||
2023-01-10 19:22:45 -0500 | 2023-01-06 | S | 629 | $36.79 | a | 204,299 | direct | yes | 1.6204 | -5.1634 | 2.9662 | 3 | -5.1634 | 6 | ||
2023-01-04 21:33:55 -0500 | 2022-12-30 | M | 5,000 | $6.88 | a | 36,667 | direct | 3.9921 | 4.0202 | 4.0202 | 6 | 0.0 | 1 | |||
2023-01-04 21:33:55 -0500 | 2022-12-30 | M | 5,000 | d | 447,000 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 22:15:03 UTC | 3.8936 | 0.4264 | 1100000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 21:45:04 UTC | 3.8936 | 0.4264 | 1100000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 21:15:04 UTC | 3.8936 | 0.4264 | 1100000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 20:45:03 UTC | 3.8936 | 0.4264 | 1100000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 20:15:04 UTC | 3.8936 | 0.4264 | 1100000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 19:45:03 UTC | 3.8936 | 0.4264 | 1100000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 19:15:03 UTC | 3.8936 | 0.4264 | 1100000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 18:45:04 UTC | 3.902 | 0.418 | 1100000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 18:15:03 UTC | 3.902 | 0.418 | 1100000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 17:45:03 UTC | 3.902 | 0.418 | 1100000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 17:15:04 UTC | 3.902 | 0.418 | 1100000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 16:45:03 UTC | 3.5655 | 0.7545 | 1100000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 16:15:03 UTC | 3.5655 | 0.7545 | 1100000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 15:45:03 UTC | 3.5655 | 0.7545 | 1100000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 15:15:04 UTC | 3.5655 | 0.7545 | 650000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 14:45:04 UTC | 3.5655 | 0.7545 | 650000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 14:15:03 UTC | 3.5655 | 0.7545 | 1100000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 13:45:03 UTC | 3.9101 | 0.4099 | 1100000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 13:15:03 UTC | 3.9101 | 0.4099 | 1100000 |
AMYLYX PHARMACEUTICALS INC AMLX | 2023-01-27 12:45:03 UTC | 3.9101 | 0.4099 | 1100000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | AMLX | -12500.0 shares, $-351875.0 | 2022-09-30 | N-PORT |
Congress Person | Party | Chamber | Filing | Filing Date | Transaction Date | Security Type | Owner | Transaction | Amount | |
---|---|---|---|---|---|---|---|---|---|---|
![]() |
Hon. Christopher L. Jacobs | republican | House | Filing | 2022-11-11 | 2022-10-12 | P | $1,001-$15,000 |